Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 7,836

Document Document Title
WO/2019/163732A1
The present invention addresses the problem of providing a novel squarylium dye which enables a coloring resin composition to achieve chromaticity values equivalent to those of coloring resin compositions that contain conventional squary...  
WO/2019/158719A1
A process is provided for the production of bis-choline tetrathiomolybdate, the process comprising reacting a choline salt with ammonium tetrathiomolybdate, wherein the choline salt is a hydroxide, acetate, or halide choline salt, wherei...  
WO/2019/154647A1
The invention relates to a method for continuously producing C2-C4 mono-alkanolamines by reacting a corresponding C2-C4 alkylene oxide with a molar excess of ammonia (NH3), wherein aqueous ammonia is used, in the liquid phase and in the ...  
WO/2019/154876A1
Novel crystalline particles, methods for manufacture of crystalline particles, and solid unit dosage forms, particularly tablets or capsules, of bis-choline tetrathiomolybdate are provided. In particular, provided herein are crystalline ...  
WO/2019/154436A1
Disclosed is a preparation method for a racemic adrenaline as represented by formula 2. The method comprises the following steps: compound 1 is directly racemized in an acidic solution to produce compound 2, the acid solution comprising ...  
WO/2019/150323A1
Ionic liquids of creatine comprising a creatine anion and a cation., as well as their means of manufacture. Examples of the ionic liquids of creatine are choline creatinate, betaine ethyl ester creatinate and agmatine creatinate are desc...  
WO/2019/144132A1
Described herein are compounds that are estrogen receptor modulators of formula I' Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen rece...  
WO/2019/138216A1
The present invention relates to the field of catalytic hydrogenation and, more particularly, to methods of manganese-catalysed hydrogenation of esters to alcohols. Advantageously, where the esters are chiral, the hydrogenations proceed ...  
WO/2019/137724A1
The present invention relates to ureylene additives, a method for their preparation, a use of said ureylene additives favorably as additive in metal or metal alloy deposition composition, preferably in a copper or copper alloy deposition...  
WO/2019/140038A1
The invention provides branched hydrophobes for the production of surfactants with improved properties over linear hydrophobes. The invention also provides branched C10-12 enals and aldehydes that are oxidized to branched fatty acids or ...  
WO/2019/135949A1
N-hydroxyalkylated polyamines, methods of making N-hydroxyalkylated polyamines, and drilling fluids containing N-hydroxyalkylated polyamines are provided, in which the N-hydroxyalkylated polyamine includes Formula (I): where R1 and R2 ar...  
WO/2019/129710A1
The disclosure provides methods for making a quaternary ammonium compound, such as comprising: providing an amine composition comprising an amine of the formula R[CONH(CH2)n]zN(R1)(R2), wherein z is 0-1, n is 2-5, R is C10-C22 alkyi or C...  
WO/2019/119293A1
The present invention concerns new cationic quaternary ammonium compounds which exhibit excellent adsorption properties on negatively charged surfaces. These ones can notably be obtained firstly by reacting an internal ketone with a twin...  
WO/2019/121379A1
The present invention relates to the improved synthesis of chlorinated acetophenones (CAP) of formula (I). Particularly, the invention shows a way how to reduce the use of chlorinated solvents and the formation of chlorinated volatile by...  
WO/2019/109610A1
Disclosed are an aqueous agent and powder of a Gemini-type shale inhibitor for water-based drilling fluids, preparation methods therefor, and an inhibitor. After adding the Gemini-type shale inhibitor for water-based drilling fluids to a...  
WO/2019/105881A1
The invention relates to a novel and improved method for producing (3S)-3-(4-chlor-3-{[(2S,3R)-2-(4-chlorphenyl)-4,4,4-trifluor -3-methylbutanoyl]amino}phenyl)-3-cyclo-propylpropanoic acid of the formula (I), to the compound of the formu...  
WO/2019/107533A1
The present invention provides a compound for suppressing cell transformation, the compound being represented by the following general formula (wherein n is 1 or 2; R1 is H, methoxy(-OCH3), or Cl; R2 is H, -OCH3, or Cl; R3 is H, -OCH3, C...  
WO/2019/105324A1
Disclosed is a method for preparing salicylamide acetate. The method comprises the steps of: (1) carrying out amino protection on salicylaldehyde having a structure represented by formula 1 to obtain a compound having a structure represe...  
WO/2019/102311A1
The invention provides the tris salt of 4-(4-(1-isopropyl-7-oxo-1,4,6,7- tetrahydrospiro[indazole-5,4'-piperidine]-1'-carbonyl)-6-met hoxypyridin-2-yl)benzoic acid as a crystalline anhydrous or tri-hydrate; as well as polymorphs, pharmac...  
WO/2019/086707A1
The present invention relates to a method of reducing the number or percentage of pluripotent stem cells or of enriching differentiating or differentiated cells in a cell population comprising pluripotent stem cells and differentiating c...  
WO/2019/081283A1
The invention relates to a method for purifying a mixture containing MEG, MEA, EDA and DETA, as well as low-boiling components having a boiling point lower than or the same as that of PIP, and high-boiling components having a boiling poi...  
WO/2019/070169A1
The invention relates to a water-soluble liophilised form of (bis(2-thio-4,6-dioxo-1,2,3,4,5,6-hexahydropyrimidine-5-yl)- (4-nitrophenyl)methane) which has hepatoprotective activity and is designed to be used in medicine for the treatmen...  
WO/2019/062665A1
The present invention discloses a linker compound, a polyethylene glycol-linker conjugate and a derivative thereof, and a polyethylene glycol-linker drug conjugate. The linker compound and the polyethylene glycol conjugate and a derivati...  
WO/2019/053426A1
There is herein provided a compound of formula (I).  
WO/2019/053494A1
The present invention relates to a process of preparation of O-Desmethyl tramadol through potassium hydroxide mediated demethylation of Tramadol under phase transfer conditions.  
WO/2019/053429A1
There is herein provided a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein X, R1, R 2, R 3, R 4 and n have meanings as provided in the description.  
WO/2019/041961A1
Provided are a transparent nucleating agent, a preparation method therefor and the use thereof, wherein the transparent nucleating agent comprises a compound represented by formula (1) and a derivative thereof; the method comprises: brin...  
WO/2019/035775A1
A method for the preparation of tapentadol in the form of a base or its hydrogen chloride, which involves the preparation of a salt (III) from a mixture of diastereomers (II) by means of crystallization-induced asymmetric transformation ...  
WO/2019/030194A1
The invention relates to a process for manufacturing polyethyleneannine compounds selected from the group of polyethyleneamines and hydroxyethylethyleneamines comprising the steps of - in an adduction step providing a CO2 adduct of a sta...  
WO/2019/026994A1
The present invention provides a pharmaceutical composition for the treatment or prevention of cognitive function diseases or disorders, wherein the pharmaceutical composition contains a compound represented by formula (I), an enantiomer...  
WO/2019/022251A1
A (poly)amine compound represented by formula (0): (in formula (0), RX represents a C1-70 2nA-valent group or a single bond; R1A each independently represent an optionally substituted C1-30 alkyl group, an optionally substituted C6-30 ar...  
WO/2019/020466A1
Process for the hydrolysis or alcoholysis of a ketal or acetal compound wherein a ketal or acetal compound comprising at least one ketal or acetal group and at least one amino group is reacted with carbon dioxide and water oran alcohol.  
WO/2019/009317A1
Provided are: a novel compound usable as an organic tag which has a high stability under acidic conditions in peptide synthesis, etc.; and a method for highly efficiently producing a peptide wherein the compound is used as an organic tag.  
WO/2019/002371A1
A method of preparing a sterilized injectable hydrogel composition, comprising the steps: a) providing a covalently crosslinked glycosaminoglycan, b) swelling the covalently crosslinked glycosaminoglycan in a solution comprising Bis-Tris...  
WO/2018/228981A1
The invention relates to a process for the preparation of a compound represented by formula (I) wherein X is selected from the group consisting of -H, -halogen, linear or branched C1-C7 alkyl group, linear or branched C1-C5 alkoxy group,...  
WO/2018/227012A1
The present invention provides compositions (e.g., nanoparticles) comprising a conjugated polyethyleneimine (PEI) polymer (a "conjugated lipomer"), or a pharmaceutically acceptable salt thereof, and a lipid-PEG conjugate, wherein the con...  
WO/2018/224315A1
The invention relates to a method for producing alkanolamines and/or ethyleneamines in the liquid phase by reacting ethylene glycol and/or monoethanolamine with ammonia in the presence of an amination catalyst which contains one or more ...  
WO/2018/224316A1
The invention relates to a method for producing alkanolamines and/or ethyleneamines in the liquid phase, by reacting ethylene glycol and/or monoethanolamine with ammonia in the presence of an amination catalyst containing Co, Ru and Sn.  
WO/2018/224321A1
The invention relates to a method for producing alkanolamines and/or ethyleneamines in the liquid phase, by reacting ethylene glycol and/or monoethanolamine with ammonia in the presence of an amination catalyst obtained by reducing a cat...  
WO/2018/214877A1
Disclosed is a crystal form of dezocine. The X-ray powder diffraction (XRD) pattern thereof is determined using Cu/K-α1, and has a diffraction peak at the 2θ value of 9.1±0.2 and 12.2±0.2, and the height% of these diffraction peaks a...  
WO/2018/195956A1
Provided is a method for preparing a single crystal of an anhydrous halogenated choline or a derivative thereof, comprising the steps of: (1) proportionally weighing the halogenated choline or a derivative thereof, an alcohol or ether co...  
WO/2018/199166A1
The purpose of the present invention is to provide: compounds having a TrkA inhibiting effect, or pharmacologically acceptable salts thereof, or solvates of these; pharmaceutical compositions characterized by containing these as an activ...  
WO/2018/196860A1
The present invention relates to the field of chemical synthesis, and in particular to an ammonium carboxylate compound, a crystal form and an amorphous substance thereof, and a preparation method therefor. The present invention prepares...  
WO/2018/200618A1
The present invention provides novel compounds as well as compositions and methods using the same for preventing and/or treating degenerative disorders of the central nervous system and/or lysosomal storage disorders. In particular, the ...  
WO/2018/191719A1
A method of treating a disease mediated by protein expression in adipose tissue by intraperitoneally administering a composition comprising a lipid nanoparticle encapsulating or associated with a therapeutic agent (e.g., a nucleic acid),...  
WO/2018/191657A1
Compounds are provided having the following structure: Formula (I) or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R, R1, R2, G1, G2 and n are as defined herein. Use of the compounds as a component of lip...  
WO/2018/185613A1
The present invention relates to an additive composition for controlling and inhibiting polymerization of monomers, wherein the composition comprises a combination of (a) a phenol compound comprising catechol compound with (b1) an alipha...  
WO/2018/181986A1
The present invention provides a pharmaceutical composition for treating or preventing cognitive function disease or disorder, the composition comprising a compound represented by formula (I), an enantiomer thereof, a diastereomer thereo...  
WO/2018/178142A1
The present invention is directed to crystalline salt of 5-methyl-(6S)-tetrahydrofolic acid comprising (i) 5-methyl-(6S)-tetrahydrofolic acid, (ii) sodium and (iii) an organic base having a pKa value from 6 to 11; wherein the molar ratio...  
WO/2018/172133A1
Compounds of formula (I), wherein the subsitiuents are as defined in claim 1. Furthermore, the present invention relates to agrochemical compositions which comprise compounds of formula (I), to preparation of these compositions, and to t...  

Matches 1 - 50 out of 7,836